Loading clinical trials...

RECRUITINGNA

Gastric Feeding Versus Transpyloric Feeding in Infants with Severe Bronchopulmonary Dysplasia, a Crossover Study

N-of-1 Trial Comparing Prolonged Gastric Feeding to Transpyloric Feeding in Infants with Severe Bronchopulmonary Dysplasia

NCT06821776•Le Bonheur Children's Hospital

View on ClinicalTrials.gov

Summary

Hospitalized infants with severe bronchopulmonary dysplasia (BPD) and feeding intolerance will be randomized to 2 weeks of continuous gastric feeding or continuous transpyoloric feeding. Subjects will crossover after 2 weeks and receive 4 weeks of each feeding mode. Respiratory status will be assessed to determine the optimal feeding mode for each infant.

Eligibility

Age

0 - 1 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patients born \<32 weeks' gestation
•Currently admitted to the Le Bonheur NICU
•Grad 2 or 3 BPD (positive pressure or intubated at 36 weeks PMA)
•Signs of gastroesophageal reflux, chronic aspiration, or other feeding intolerance.

Exclusion Criteria

•Known gastrointestinal anomalies
•Unable to tolerate ≥100mL/kg/day enteral feeding
•Congenital anomalies likely to alter feeding techniques
•Surgical feeding tube in place or expected within the next 8 weeks
•Expected to remain hospitalized \<8 weeks

Locations (1)

Le Bonheur Children's Hospital

Memphis, Tennessee, United States

Key Dates

Start Date

February 5, 2025

Primary Completion Date

February 1, 2030

Completion Date

February 1, 2030

Last Updated

February 12, 2025

Enrollment

ESTIMATED participants

Conditions

Bronchopulmonary DysplasiaFeeding Intolerance

Interventions

Gastric feeding

PROCEDURE

Transpyloric feeding

PROCEDURE

IVIG Trial for the Treatment of Bronchopulmonary Dysplasia

NCT06925360

Bronchopulmonary Dysplasia

View study

RECRUITING

Reversibility of Bronchial Obstruction in Children Born Preterm

NCT06110481

Bronchopulmonary DysplasiaChronic Lung Disease of Prematurity+5 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 12, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Gastric Feeding Versus Transpyloric Feeding in Infants with Severe Bronchopulmonary Dysplasia, a Crossover Study

Inclusion Criteria

Exclusion Criteria

IVIG Trial for the Treatment of Bronchopulmonary Dysplasia

Reversibility of Bronchial Obstruction in Children Born Preterm

The Role of Volatile Organic Compounds (VOCs), Airway Mucins and the Microbiome in the Early Prediction of Bronchopulmonary Dysplasia (BPD)

Comparison of INRECSURE and LISA in Preterm Neonates With RDS

Follow-Up Study of Safety and Efficacy of Pneumostem® in Premature Infants With Bronchopulmonary Dysplasia

Consequences of Antiangiogenic Factors Involved in Preeclampsia on Intra-uterine Growth Restricted Preterm Newborn